ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,050 GBX | -0.87% |
|
+0.52% | +13.68% |
| May. 03 | Angle shares up on assay development deal with AstraZeneca | AN |
| May. 03 | Angle shares up on assay development deal with AstraZenaca | AN |
Financials (USD)
| Sales 2024 * | 51.18B | Sales 2025 * | 54.8B | Capitalization | 234B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B | Net income 2025 * | 10.19B | EV / Sales 2024 * | 4.97 x |
| Net Debt 2024 * | 20.03B | Net Debt 2025 * | 13.54B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
27.9
x | P/E ratio 2025 * |
23.3
x | Employees | 89,900 |
| Yield 2024 * |
2.05% | Yield 2025 * |
2.14% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.87% | ||
| 1 week | +0.52% | ||
| Current month | -0.10% | ||
| 1 month | +14.09% | ||
| 3 months | +16.31% | ||
| 6 months | +17.33% | ||
| Current year | +13.68% |
1 week
11 886.00
12 488.00
1 month
10 504.0012 488.00
Current year
9 461.0012 488.00
1 year
9 461.0012 488.00
3 years
7 556.0012 488.00
5 years
5 642.0012 488.00
10 years
3 680.0012 488.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +12.44% | ||
| 5.17% | 18 M€ | +3.01% | - | |
| 4.89% | 776 M€ | +8.83% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 12,050 | -0.87% | 1,642,783 |
| 24-05-02 | 12,156 | -0.12% | 2,006,478 |
| 24-05-01 | 12,170 | +0.90% | 867,636 |
| 24-04-30 | 12,062 | +0.32% | 2,564,143 |
| 24-04-29 | 12,024 | +0.30% | 3,704,143 |
Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
164.5
USD
Spread / Average Target
+8.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.68% | 234B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B | |
| +1.72% | 123B |
- Stock Market
- Equities
- AZN Stock
